Valeant will buy eye surgery device maker Synergetics

September 2, 2015

Canadian drugmaker Valeant Pharmaceuticals said Wednesday it will buy eye surgery product maker Synergetics USA for as much as $192 million.

Valeant has already announced two acquisitions worth at least $1 billion this year, so the purchase is relatively small by its standards. But the company said Synergetics' products will strengthen the business of Bausch + Lomb, which it bought for $8.7 billion in 2013. Synergetics makes products used in surgeries on the back of the eye, as well as surgical equipment and other products.

The Quebec-based company said it will pay $6.50 per share, or $166.2 million, for Synergetics. Valeant could make payments worth another $1 per share, or $25.6 million, if Synergetics reaches $65 million in annual sales of ophthalmology products over the next few years.

Synergetics USA Inc., based in O'Fallon, Missouri, had $64.8 million in revenue in the fiscal year that ended on July 31, 2014. It said $35.2 million came from ophthalmic products and the rest came from surgical generators and other products.

Shares of Synergetics climbed $2.19, or 50 percent, to close at $6.58, and Valeant shares rose $8.13, or 3.6 percent, to $232.18.

In April Valeant paid $11.11 billion for Salix Pharmaceuticals, gaining products including Pepcid and Zegerid for ulcers and the constipation treatment Relistor. In August it agreed to buy Sprout Pharmaceuticals for $1 billion. That announcement came days after the Food and Drug Administration approved Sprout's drug Addyi, the first prescription drug intended to boost sexual desire in women.

On Tuesday the company said it will work with AstraZeneca PLC on a potential psoriasis drug. It could pay AstraZeneca $445 million and the companies will share profits.

Valeant Pharmaceuticals International Inc. had $8.26 billion in revenue in 2014.

Explore further: Valeant to spend about $1B on maker of women's libido drug

Related Stories

Valeant to spend about $1B on maker of women's libido drug

August 20, 2015
Valeant Pharmaceuticals will pay about $1 billion in cash to buy Sprout Pharmaceuticals, the maker of the first prescription drug intended to boost sexual desire in women.

Valeant ups Salix bid to $11.11B and Endo ends quest (Update)

March 16, 2015
Valeant raised its offer for Salix Pharmaceuticals Ltd. by more than $1 billion Monday, forcing rival bidder Endo International out of the running.

Valeant steps in to work on psoriasis drug with AstraZeneca

September 1, 2015
Canadian drugmaker Valeant will work with British competitor AstraZeneca on a potential treatment for psoriasis a few months after biotech giant Amgen said it was ending research on the drug because of a link to suicidal ...

Endo Intl. tops Valeant's offer for fellow drugmaker Salix (Update)

March 11, 2015
Specialty drugmaker Endo International PLC is trying to lure Salix Pharmaceuticals Ltd. with an offer Endo said is worth 11 percent more than the $10 billion Salix has agreed to accept from serial acquirer Valeant Pharmaceuticals ...

Allergan tells shareholders to reject Valeant deal

June 23, 2014
Allergan, the maker of Botox, said Monday that Valeant Pharmaceuticals' hostile takeover bid for the company is "grossly inadequate" and that shareholders should reject it.

Valeant pitches potential eye drug, research focus

September 25, 2014
Valeant Pharmaceuticals is drawing attention to a potential glaucoma treatment and its focus on product development, as the Canadian drugmaker continues to build its case to investors for a takeover of Botox-maker Allergan.

Recommended for you

How do babies laugh? Like chimps!

November 7, 2018
Few things can delight an adult more easily than the uninhibited, effervescent laughter of a baby. Yet baby laughter, a new study shows, differs from adult laughter in a key way: Babies laugh as they both exhale and inhale, ...

Tongue-in-cheek Nobels honor nutritional analysis of cannibalism, roller-coaster kidney stones treatment

September 14, 2018
A nutritional analysis of cannibalism and treating kidney stones on roller-coasters were research projects honored by tongue-in-cheek awards at Harvard University Thursday, designed to make you laugh first, and think later.

Pediatric robot patient offers new level of realism for doctors in training

September 10, 2018
A team of researchers and engineers at Gaumard Scientific has unveiled a new robot that raises the bar on medical training devices. The robot, called HAL, has been made to look like a five-year-old male patient and offers ...

Why men say they've had more lifetime sexual partners than women

July 25, 2018
The disparity between the number of sexual partners reported by men and women can largely be explained by a tendency among men to report extreme numbers of partners, and to estimate rather than count their lifetime total, ...

Censors jump into action as China's latest vaccine scandal ignites

July 22, 2018
Chinese censors on Sunday deleted articles and postings about the vaccine industry as an online outcry over the country's latest vaccine scandal intensified.

Revenge of a forgotten medical 'genius'

June 30, 2018
It's not an uncommon fate for a pioneering scientist: languishing unrecognised in his time before dying in obscurity. But as his 200th birthday approaches, the life-saving work of a Hungarian obstetrician is finally getting ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.